Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.

摘要: Background: CD44 is a potentially interesting prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). Although the expression of has been reported to correlate with poor prognosis NSCLC most literatures, some controversies still exist. Since limited patient numbers within independent studies, here we performed meta-analysis clarify correlations between clinicopathological features NSCLC. Methods: Relevant literatures were identified using PubMed, EMBASE CNKI (China National Knowledge Infrastructure) databases (up February 2014). Data from eligible studies extracted included into random effects model. Studies pooled. Summary hazard ratios (HR) clinical parameters calculated. Results: We final analysis 1772 patients 23 evaluable for Prognostic Value 2167 28 features. Our study shows that pooled ratio overexpression CD44-V6 overall survival was 1.63 [95% confidence interval (CI): 1.20-2.21] by univariate 1.29 (95% CI: 0.71-2.37) multivariate analysis.The HR overexprssion panCD44 1.53 0.58-4.04) 3.00 1.53-5.87) analysis. Overexpression associated tumor differentiation (poor differentiation, OR = 1.66, 95% 1.12-2.45), histological type [squamous carcinomas (SCC), 2.6, 1.63-5.02], TMN stage (TMN III, 2.22, 1.44-3.43) lymph node metastasis (N1-3, 3.52, 2.08-5.93) However, there no significant association size [T category, 1.42, 0.73-2.78]. Conclusion: showed an efficient factor significantly type, metastasis. size. Large prospective are now needed confirm utility as marker.